How to Cite
Abstract
Kawasaki disease, also known as mucocutaneous lymphatic syndrome, from unknown etiology, and characterized by an acute vasculitis which affects predominantly medium-sized arteries, and has a predisposition to form coronary artery aneurysms. It is described as a febrile illness in children under five years old with a genetic predisposition in Asian countries, such as Japan. Being a rare disease, the diagnosis is clinical so, no complementary studies are needed to confirm it and it can be followed with important sequelae if treatment is not started early. The main treatment is based in intravenous immunoglobulin and acetylsalicylic acid, both used with the purpose of reducing the duration of the fever and inflammation, in addition to prevent coronary artery aneurysms.
Keywords
References
(1) Kim GB. Reality of Kawasaki disease epidemiology. Korean J Pediatr. 2019; 62(8)292-296. https://doi.org/10.3345/kjp.2019.00157
(2) Lee DS. Does any specific infection cause Kawasaki disease? Korean J Pediatr. 2019;62(6): 213-214. https://doi.org/10.3345/kjp.2019.00129
(3) Singh S, Jindal AK, Pilania RK. Diagnosis of Kawasaki disease. International Journal of Rheumatic Diseases. 2018;21(1):36-44. https://doi.org/10.1111/1756-185X.13224
(4) Sosa T, Browner L, Divanovic A. Diagnosis and Management of Kawasaki. JAMA Network Clinical Guidline Synopsis. 2019;173(3):278-279.https://doi.org/10.1001/jamapediatrics.2018.3307
(5) Kuo HC. Preventing coronary artery lesions in Kawasaki disease. Biomedical Journal XXX. 2017; 40(3):141-146. https://doi.org/10.1097/MCA.0000000000000792
(6) Ramphul K, Mejias SG, Joynauth J. Kawasaki disease among children in the United States. Reumatología. 2019;57(4): 253-254. https://doi.org/10.5114/reum.2019.87618
(7) Son MBF, Newburger JW. Kawasaki Disease. Pediatrics in Review. 2018;39(2):78-92. https://doi.org/10.1542/pir.2016-0182
(8) Fuller MG. Kawasaki Disease in Infancy. Advanced Emergency Nursing Journal. 2019;41(3): 222-228. https://doi.org/10.1097/TME.0000000000000253
(9) Pasma H, Honkila M, Pokka T, Renko M, Salo E, Tapiainen T. Epidemiology of Kawasaki disease before and after universal Bacille Calmette-Guérin vaccination program was discontinued. Acta Pediátrica Wiley. 2019; 00: 1-5. https://doi.org/10.1111/apa.15012
(10) Marrani E, Burns JC, Cimaz R. How Sould We Classify Kawasaki Disease? Frontiers in Immunology. 2018; 9:2974. https://doi.org/10.3389/fimmu.2018.02974
(11) Shulman St, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nature Reviews Rheumatology. 2015; 11, 475-482. https://doi.org/10.1038/nrrheum.2015.54
(12) Moreno MA. Summarizing What Has Been Learned About Kawasaki Disease. JAMA Pediatrics Patient Page. 2016;170(11):1124. https://doi.org/10.1177/0009922817729483
(13) Jindal AK, Pilania RK, Prithvi A, Guleria S, Singh S. Kawasaki disease: characteristics, diagnosis and usual presentations. Expert Review of Clinical Immunology. 2019; 15(10):1089-1104. https://doi.org/10.1080/1744666X.2019.1659726
(14) Ishii M, Kato H. History and Future of Treatment for Acute Stage Kawasaki Disease. Korean Circulation Journal. 2020; 50(2):e9. https://doi.org/10.4070/kcj.2019.0290
(15) Esposito S, Bianchini S, Dellepiane RM, Principi N. Vaccines and Kasawaki disease. Expert Review of Vaccines. 2016;15(3):417-24. https://doi.org/10.1586/14760584.2016.1128329